Percutaneous image-guided biopsy in malignant peripheral nerve sheath tumors.
Malignant peripheral nerve sheath tumor
Neurologic deficit
Percutaneous image-guided biopsy
Tissue diagnosis
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
06
2020
accepted:
26
08
2020
pubmed:
10
9
2020
medline:
13
5
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
The decision to biopsy a peripheral nerve tumor is largely based on its presumed behavior and prognosis, determined by patient history, clinical exam, and radiologic characteristics. Percutaneous image-guided biopsy is not without risk in patients with malignant peripheral nerve sheath tumors (MPNSTs); in particular, there may be concern regarding worsening neurologic function, increasing neuropathic pain, and incorrect or absent diagnosis. Following approval by our institutional review board, we reviewed records from 1990 to 2019 at our institution's three main sites ("our institution"). Patients with pathology-proven MPNST were selected. Further inclusion criteria included image-guided percutaneous biopsy performed at our institution, pathology report available for review, and follow-up documentation to determine post-biopsy complications. Three hundred thirty-one patients with MPNST were reviewed. In total, 73 patients undergoing image-guided percutaneous biopsies were included. Twenty-two (30.1%) had biopsy-related complications. This included ten patients with misdiagnosis (13.7%) and six patients with non-diagnostic biopsies (8.2%). Six patients had new or worsened pain that resolved with time and neuropathic pain medication (8.2%), and one patient had subjectively worsened proximal weakness (1.3%) which resolved. We found nearly a third of patients undergoing biopsy had a biopsy-related complication. The single largest complication was the inability to obtain an accurate diagnosis (21.9%) with the first biopsy. This may lead to the need for repeat percutaneous or open biopsies, or a non-oncologic initial surgery with implications for disease-free and overall survival. Neurologic complications including exacerbation of pain or a deficit were rare and transient. It remains important that clinicians balance the potential risks and benefits based on individual patient characteristics when determining the necessity of an image-guided percutaneous biopsy.
Sections du résumé
BACKGROUND
The decision to biopsy a peripheral nerve tumor is largely based on its presumed behavior and prognosis, determined by patient history, clinical exam, and radiologic characteristics. Percutaneous image-guided biopsy is not without risk in patients with malignant peripheral nerve sheath tumors (MPNSTs); in particular, there may be concern regarding worsening neurologic function, increasing neuropathic pain, and incorrect or absent diagnosis.
METHODS
Following approval by our institutional review board, we reviewed records from 1990 to 2019 at our institution's three main sites ("our institution"). Patients with pathology-proven MPNST were selected. Further inclusion criteria included image-guided percutaneous biopsy performed at our institution, pathology report available for review, and follow-up documentation to determine post-biopsy complications.
RESULTS
Three hundred thirty-one patients with MPNST were reviewed. In total, 73 patients undergoing image-guided percutaneous biopsies were included. Twenty-two (30.1%) had biopsy-related complications. This included ten patients with misdiagnosis (13.7%) and six patients with non-diagnostic biopsies (8.2%). Six patients had new or worsened pain that resolved with time and neuropathic pain medication (8.2%), and one patient had subjectively worsened proximal weakness (1.3%) which resolved.
CONCLUSION
We found nearly a third of patients undergoing biopsy had a biopsy-related complication. The single largest complication was the inability to obtain an accurate diagnosis (21.9%) with the first biopsy. This may lead to the need for repeat percutaneous or open biopsies, or a non-oncologic initial surgery with implications for disease-free and overall survival. Neurologic complications including exacerbation of pain or a deficit were rare and transient. It remains important that clinicians balance the potential risks and benefits based on individual patient characteristics when determining the necessity of an image-guided percutaneous biopsy.
Identifiants
pubmed: 32901394
doi: 10.1007/s00701-020-04556-7
pii: 10.1007/s00701-020-04556-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
515-519Références
Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P (2015) Diagnostic accuracy of PET/CT-guided percutaneous biopsies for malignant peripheral nerve sheath tumors in neurofibromatosis type 1 patients. PLoS One 10:e0138386. https://doi.org/10.1371/journal.pone.0138386
doi: 10.1371/journal.pone.0138386
pubmed: 26445379
pmcid: 4596851
Graham DS, Russell TA, Eckardt MA, Motamedi K, Seeger LL, Singh AS, Bernthal NM, Kalbasi A, Dry SM, Nelson SD, Elashoff D, Levine BD, Eilber FC (2019) Oncologic accuracy of image-guided percutaneous core-needle biopsy of peripheral nerve sheath tumors at a high-volume sarcoma center. Am J Clin Oncol 42:739–743. https://doi.org/10.1097/COC.0000000000000591
doi: 10.1097/COC.0000000000000591
pubmed: 31436746
Makise N, Sekimizu M, Kubo T, Wakai S, Hiraoka N, Komiyama M, Fukayama M, Kawai A, Ichikawa H, Yoshida A (2018) Clarifying the distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma: a critical reappraisal of the diagnostic utility of MDM2 and H3K27me3 status. Am J Surg Pathol 42:656–664. https://doi.org/10.1097/PAS.0000000000001014
doi: 10.1097/PAS.0000000000001014
pubmed: 29309298
Mustapar N, Zawawi MSF, Tuan Sharif SE (2020) The value of H3K27me3 Immunohistochemistry in differentiating malignant peripheral nerve sheath tumour with its histologic mimickers. Asian Pac J Cancer Prev 21:699–705. https://doi.org/10.31557/APJCP.2020.21.3.699
doi: 10.31557/APJCP.2020.21.3.699
pubmed: 32212796
pmcid: 7437312
Ogose A, Hotta T, Morita T, Higuchi T, Umezu H, Imaizumi S, Hatano H, Kawashima H, Gu W, Endo N (2004) Diagnosis of peripheral nerve sheath tumors around the pelvis. Jpn J Clin Oncol 34:405–413. https://doi.org/10.1093/jjco/hyh072
doi: 10.1093/jjco/hyh072
pubmed: 15342668
Pendleton C, Spinner RJ (2020) Image-guided percutaneous biopsy of peripheral nerve tumors of indeterminate nature: risks and benefits. Acta Neurochir 162:1425–1429. https://doi.org/10.1007/s00701-020-04257-1
doi: 10.1007/s00701-020-04257-1
pubmed: 32040620
Perez-Roman RJ, Shelby Burks S, Debs L, Cajigas I, Levi AD (2020) The risk of peripheral nerve tumor biopsy in suspected benign etiologies. Neurosurgery 86:E326–E332. https://doi.org/10.1093/neuros/nyz549
doi: 10.1093/neuros/nyz549
pubmed: 31927583
Pianta M, Chock E, Schlicht S, McCombe D (2015) Accuracy and complications of CT-guided core needle biopsy of peripheral nerve sheath tumours. Skelet Radiol 44:1341–1349. https://doi.org/10.1007/s00256-015-2185-6
doi: 10.1007/s00256-015-2185-6
Reuss DE, Habel A, Hagenlocher C, Mucha J, Ackermann U, Tessmer C, Meyer J, Capper D, Moldenhauer G, Mautner V, Frappart PO, Schittenhelm J, Hartmann C, Hagel C, Katenkamp K, Petersen I, Mechtersheimer G, von Deimling A (2014) Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathol 127:565–572. https://doi.org/10.1007/s00401-014-1246-6
doi: 10.1007/s00401-014-1246-6
pubmed: 24464231
Tottrup M, Eriksen JD, Hellfritzsch MB, Sorensen FB, Baad-Hansen T (2020) Diagnostic accuracy of ultrasound-guided core biopsy of peripheral nerve sheath tumors. J Clin Ultrasound 48:134–138. https://doi.org/10.1002/jcu.22769
doi: 10.1002/jcu.22769
pubmed: 31441068